Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 12.56 is 22% below its 5-year average of 16.18, near the low end of its 5-year range (0.46–70.97).
As of the fiscal period ended Tuesday, June 30, 2026. 12.97% above its 12-month average of 11.12.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 12.56.
CURRENT RATIO
12.56
CURRENT RATIO AVG TTM
11.12
CURRENT RATIO AVG 3Y
30.79
CURRENT RATIO AVG 5Y
16.18
CURRENT RATIO AVG 10Y
N/A
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+12.97%
CURRENT VS 3Y AVG
-59.21%
CURRENT VS 5Y AVG
-22.40%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.75
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+234.88%
vs the sector median at left
MoonLake Immunotherapeutics
Market Cap
$921.06M
Current Ratio
12.56
TTM Avg
11.12
3Y Avg
30.79
5Y Avg
16.18
Market Cap
$929.83M
Current Ratio
18.00
TTM Avg
17.46
3Y Avg
17.46
5Y Avg
17.46
Market Cap
$953.81M
Current Ratio
16.33
TTM Avg
11.68
3Y Avg
16.13
5Y Avg
16.13
Market Cap
$887.99M
Current Ratio
16.16
TTM Avg
3.88
3Y Avg
3.97
5Y Avg
4.50
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | $921.06M | 12.56 | 11.12 | 30.79 | 16.18 |
| CeriBell, Inc. (CBLL)vs › | $923.53M | 9.18 | 13.23 | 9.24 | 9.24 |
| HealthStream, Inc. (HSTM)vs › | $914.73M | 1.06 | 1.14 | 1.09 | 1.06 |
| Seaport Therapeutics, Inc. Common Stock (SPTX)vs › | $929.83M | 18.00 | 17.46 | 17.46 | 17.46 |
| Kura Oncology, Inc. (KURA)vs › | $934.79M | 4.73 | 7.76 | 11.59 | 15.68 |
| Savara Inc. (SVRA)vs › | $952.91M | 10.13 | 12.79 | 15.81 | 14.15 |
| Aktis Oncology, Inc. (AKTS)vs › | $953.81M | 16.33 | 11.68 | 16.13 | 16.13 |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $887.99M | 16.16 | 3.88 | 3.97 | 4.50 |
| Bioventus Inc. (BVS)vs › | $887.50M | 1.69 | 1.50 | 1.36 | 1.44 |
| Arbutus Biopharma Corp (ABUS)vs › | $884.97M | 81.42 | 11.94 | 8.59 | 10.34 |
Current Ratio
12.56
Quick Ratio
12.56
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 12.56 |
| 2026-03-31 | 8.60 |
| 2025-12-31 | 9.27 |
| 2025-09-30 | 8.50 |
| 2025-06-30 | 16.65 |
| 2025-03-31 | 21.11 |
| 2024-12-31 | 21.11 |
| 2024-09-30 | 25.51 |
| 2024-06-30 | 43.71 |
| 2024-03-31 | 62.13 |
| 2023-12-31 | 51.59 |
| 2023-09-30 | 48.51 |
| 2023-06-30 | 70.97 |
| 2023-03-31 | 9.14 |
| 2022-12-31 | 9.98 |
| 2022-09-30 | 14.71 |
| 2022-06-30 | 25.51 |
| 2022-03-31 | 0.57 |
| 2021-12-31 | 0.46 |
| 2021-09-30 | 0.59 |
| 2021-06-30 | 14.79 |
| 2021-03-31 | 24.33 |
| 2020-12-31 | 12.93 |
